Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DEVELOPMENT OF NEW ANTICANCER AGENTS IN C HILDREN - METHODOLOGY, DIFFICULTIES, AND STRATEGIES
Autore:
VASSAL G; PEIN F; GOUYETTE A; LEMERLE J;
Indirizzi:
INST GUSTAVE ROUSSY,DEPT PEDIAT,39 RUE CAMILLE DESMOULINS F-94805 VILLEJUIF FRANCE
Titolo Testata:
Annales de pediatrie
fascicolo: 8, volume: 41, anno: 1994,
pagine: 477 - 484
SICI:
0066-2097(1994)41:8<477:DONAAI>2.0.ZU;2-U
Fonte:
ISI
Lingua:
FRE
Keywords:
PHASE-I TRIALS; CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
NO
Recensione:
Indirizzi per estratti:
Citazione:
G. Vassal et al., "DEVELOPMENT OF NEW ANTICANCER AGENTS IN C HILDREN - METHODOLOGY, DIFFICULTIES, AND STRATEGIES", Annales de pediatrie, 41(8), 1994, pp. 477-484

Abstract

Survival in children with cancer has improved dramatically over the last 20 years. Although cure is achieved in two-thirds of cases overall, the prognosis remains grim in some malignancies. New drugs are needed to improve cure rates and quality of life in children with cancer. New drugs for children are first subjected to Phase I trials, of which the methodological, ethical, and legal aspects are discussed herein. In Europe, the main problem is obtaining new drugs from the pharmaceutical companies that design them. The conduct of preclinical studies evaluating the efficacy of new drugs on models of childhood malignancies and the implementation of regulations similar to the American Orphan Drug Act would facilitate the early clinical development of potentiallyeffective anticancer agents for children.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 04:24:43